Sign in
Taking people in United StatesNo phase

Studies how endurance exercise training affects fat tissue in adults with obesity

Tests endurance exercise training on fat tissue and insulin sensitivity in men and women.

Key facts

Who runs it
AdventHealth Translational Research Institute
Where
Baton Rouge and Orlando, United StatesSee the 2 sites
Trial code
Registry title
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise
Status
Recruiting
People taking part
70 people, planned
Started
11 Sept 2024
Expected to end
Apr 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Muscle Biopsy
  • Adipose Biopsy
  • Glucose Clamp
  • Accelerometer
  • Endurance Exercise
  • Physical activity/ dietary habits
  • Heavy Water Labeling Period
Record updated
27 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men and pre-menopausal women aged 18-45 with obesity who rarely exercise. It studies how endurance exercise changes fat tissue and insulin sensitivity.

Age
18-45 years
Sex
Men and pre-menopausal women
Disease stage
BMI 30.0-40.0 kg/m2
Earlier treatment
Must be sedentary: no more than 1 day per week, lasting no more than 60 minutes, of regular endurance or resistance exercise in the past year. Many regular medicines cannot be used.

Main reasons for not taking part

  • Type 1 or Type 2 diabetes, or blood sugar or HbA1c above the set limits
  • Heart disease or a pacemaker
  • Current smoker or recent tobacco, e-cigarette or cannabis use
  • Currently pregnant, or post-partum or lactating in the last 12 months
  • MRI not possible, or not willing to have the microdialysis procedure

The registry criteria, word for word

Show all 48 criteriaShow less

Who can take part

  • Men and pre-menopausal women
  • 18-45 years of age
  • BMI 30.0-40.0 kg/m2
  • For women, if not using pharmaceutical (hormonal) contraception (i.e. birth control pills, vaginal ring, injections, or implant), must agree to use either a double barrier method as a form of birth control to prevent pregnancy (i.e. male condom with spermicide, with or without cervical cap or diaphragm); use implants or intrauterine contraceptive devices; have a tubal ligation (surgically sterile); practice abstinence; or be in an established relationship with a vasectomized or same sex partner during the entire duration of the study
  • Able to speak and understand written and spoken English
  • Sedentary defined as self-reporting no more than 1 day per week, lasting no more than 60 minutes, of regular (structured) endurance or resistance exercise in the past year
  • Must be willing to be randomized to either study group
  • Must be willing to adhere to all study procedures
  • Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study

Who cannot take part

  • Receiving active treatment (including monoclonal antibodies) for autoimmune disorders within the last 6 months
  • Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting
  • Previous bariatric or other surgery for obesity
  • Participants who fulfill any of the contraindications for MRI including metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos
  • Diagnosis of Type 1 or Type 2 diabetes mellitus
  • Self-reported history or presence of the following cardiovascular conditions: congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, stroke, symptomatic peripheral artery disease, stable angina, myocardial infarction or coronary revascularization within 6 months; clinically significant abnormalities on ECG, presence of cardiac pacemaker, or implanted cardiac defibrillator; inability to complete the VO2max test
  • Serious digestive disorders including severe gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), Crohn's disease, chronic constipation and/or diarrhea, etc
  • Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy
  • Current or history of eating disorders
  • Abnormal bleeding or coagulopathy (self-report) or history of a bleeding disorder or clotting abnormality
  • Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
  • Alcohol consumption >7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)
  • Known allergy to lidocaine or other local anesthetic
  • History of cancer (other than non-melanoma skin cancer) within the last 5 years (not in remission); anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months
  • Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year
  • Polycystic Ovarian Syndrome (PCOS) (self-report)
  • Hospitalization for COVID-19 infection in the past 12 months; individuals who tested positive for COVID-19 but were not hospitalized must be symptom-free at least 14 days
  • Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study
  • Fasting blood glucose ≥126 mg/dL
  • HbA1c ≥ 6.5%
  • Anemia (hemoglobin <12 g/dl in men or 11 g/dl in women; Hct <34%)
  • Kidney disease (creatinine >1.6 mg/dl or estimated glomerular filtration rate <60 mL/min/1.73m2)
  • Dyslipidemia (fasting triglycerides >500 mg/dL; low-density lipoprotein cholesterol (LDL-C) >190 mg/dL)
  • Whole blood donation in the last 3 months or platelet/plasma donation in the last week or plans for donation during entire protocol period
  • Metabolic bone disease (self-report) including history of non-traumatic fracture from a standing height or less and/or current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen
  • The following medication use is exclusionary:; Dose change for any chronic-use drug in the last 3 months; Cardiovascular: beta blockers and centrally acting anti-hypertensive drugs, anticoagulants, antiarrhythmics, and antiplatelet drugs (other than aspirin ≤100 mg/day); Psychiatric: chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines (short-acting non-benzodiazepine sedative-hypnotics are allowed), mood stabilizers, antiepileptic drugs, stimulants, Attention-Deficit/Hyperactivity Disorder (ADHD) drugs, anti-psychotic drugs; Pulmonary/Inflammation: chronic oral steroids (inhaled steroids are allowed), burst/taper oral steroids more than once in the last 12 months, B2-agonists (allowed if on stable dose at least 3 months); Genitourinary: 5-alpha reductase inhibitors, daily phosphodiesterase type 5 inhibitor; Hormonal: androgenic anabolic steroids, anti-estrogens, anti-androgens, estrogens and/or progestins used for reasons other than birth control, growth hormone, insulin like growth factor-I, growth hormone releasing hormone, any drugs used to treat diabetes mellitus or lower blood glucose, metformin for any indication, any drugs used specifically to induce weight loss, any drugs used specifically to induce muscle growth/hypertrophy or augment exercise-induced muscle hypertrophy; Pain/Inflammation: narcotics and narcotic receptor agonists, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, muscle relaxants ≥2 days per week; Other: chronic systemic antimicrobials (antibiotic, antiviral, antifungal, antiparasite, etc.) for any reason, high-potency topical steroids if ≥10% surface area using rule of 9s, continuous/chronic use of antibiotics or other anti-infectives for treatment or prevention, monoclonal antibodies, anti-rejection medications/immune suppressants
  • Current smokers (smoking or use of any tobacco or e-cigarette/e-nicotine/THC/cannabis products in the last 3 months); stopped smoking <10 years at time of screening for those with a >20 pack-year smoking history or stopped smoking <5 years at time of screening for those with a <20 pack-year smoking history
  • Self-reported unstable body weight in the last 3 months (> ±5%)
  • Significant changes in the quality of the diet or the level of physical activity within the last 3 months
  • Weight >396 lb (180 kg)
  • Blood pressure >140/90 mmHg
  • Abnormal liver enzymes (>2 times the upper limit of normal) that are clinically significant
  • Night shift work in the last 6 months or planning night shift work during the study period
  • Currently pregnant (pregnancy test performed on day of DEXA scan in women of child-bearing potential); post-partum during the last 12 months; lactating during the last 12 months; planning to become pregnant during the participation period
  • Partial and/or full hysterectomy (self-report)
  • Not willing to archive biospecimens for future use
  • Not willing to undergo the microdialysis procedure
  • Unable to participate in MR assessments due to claustrophobia or physical limitations of equipment tolerances (e.g., MRI bore size) based on investigator's judgment at screening
  • Positive toxicology result from screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

Where in United States

  • Pennington Biomedical Research CenterBaton Rouge, United StatesContact: Ursula White, PhDNot yet recruiting
  • AdventHealth Translational Research InstituteOrlando, United StatesContact: Recruitment DepartmentTaking people

About the trial

What the trial wants to find out

The purpose of this research study is to study the effects of endurance exercise training on adipose (fat) tissue quality and insulin sensitivity in men and women.

The 2 groups in the trial

  • Control (CTRL) groupExisting treatment, for comparison

    Treatment: Muscle Biopsy, Adipose Biopsy, Glucose Clamp, Accelerometer, Physical activity/ dietary habits, and Heavy Water Labeling Period

  • Endurance exercise (EX) groupExisting treatment, for comparison

    Treatment: Muscle Biopsy, Adipose Biopsy, Glucose Clamp, Accelerometer, Endurance Exercise, and Heavy Water Labeling Period

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise
Plain-language title
Studies how endurance exercise training affects fat tissue in adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06602141, who can take part
Record updated
27 March 2026